Diagnostic Utility of MOG Antibody Testing in Cerebrospinal Fluid
Annals of Neurology · 2024-07 · 96 (1) · 34-45
DOI: 10.1002/ana.26931 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 09.04.2024. Verfasst von Vyanka Redenbaugh und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Myelin-Oligodendrocyte Glycoprotein, Autoantibodies, Immunoglobulin G. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, NCATS NIH HHS, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
Objective
The aim of this study was to assess the diagnostic utility of cerebrospinal fluid (CSF) myelin oligodendrocyte glycoprotein antibodies (MOG‐IgG) testing.
Methods
We retrospectively identified patients for CSF MOG‐IgG testing from January 1, 1996, to May 1, 2023, at Mayo Clinic and other medical centers that sent CSF MOG‐IgG for testing including: controls, 282; serum MOG‐IgG positive MOG antibody‐associated disease (MOGAD), 74; serum MOG‐IgG negative high‐risk phenotypes, 73; serum false positive MOG‐IgG with alternative diagnoses, 18. A live cell‐based assay assessed CSF MOG‐IgG positivity (IgG‐binding‐index [IBI], ≥2.5) using multiple anti‐human secondary antibodies and end‐titers were calculated if sufficient sample volume. Correlation of CSF MOG‐IgG IBI and titer was assessed.
Results
The pan‐IgG Fc‐specific secondary was optimal, yielding CSF MOG‐IgG sensitivity of 90% and specificity of 98% (Youden's index 0.88). CSF MOG‐IgG was positive in: 4/282 (1.4%) controls; 66/74 (89%) serum MOG‐IgG positive MOGAD patients; and 9/73 (12%) serum MOG‐IgG negative patients with high‐risk phenotypes. Serum negative but CSF positive MOG‐IgG accounted for 9/83 (11%) MOGAD patients, and all fulfilled 2023 MOGAD diagnostic criteria. Subgroup analysis of serum MOG‐IgG low‐positives revealed CSF MOG‐IgG positivity more in MOGAD (13/16[81%]) than other diseases with false positive serum MOG‐IgG (3/15[20%]) ( p = 0.01). CSF MOG‐IgG IBI and CSF MOG‐IgG titer (both available in 29 samples) were correlated (Spearman's r = 0.64, p < 0.001).
Interpretation
CSF MOG‐IgG testing has diagnostic utility in patients with a suspicious phenotype but negative serum MOG‐IgG, and those with low positive serum MOG‐IgG results and diagnostic uncertainty. These findings support a role for CSF MOG‐IgG testing in the appropriate clinical setting. ANN NEUROL 2024;96:34–45
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
- Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
- Ophthalmology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
- Department of Neurology, St Vincent's University Hospital, Dublin, Ireland.
- Department of Neurology, Mayo Clinic College of Medicine, Jacksonville, Florida, USA.
- Division of Neurology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
ORCID-Profile: Vyanka Redenbaugh, Andrew McKeon, A Sebastian Lopez Chiriboga, Nisa Vorasoot, Cristina Valencia Sanchez, Anastasia Zekeridou, Divyanshu Dubey, Grace Y Gombolay, Sean J Pittock, Eoin P Flanagan
Förderung
- NINDS NIH HHS
- NCATS NIH HHS
- National Institute of Neurological Disorders and Stroke
- National Center for Advancing Translational Sciences
Zitieren
APA
Redenbaugh, V., Fryer, J. P., Cacciaguerra, L., Chen, J. J., Greenwood, T. M., Gilligan, M., Thakolwiboon, S., Majed, M., Chia, N. H., McKeon, A., Mills, J. R., Lopez Chiriboga, A. S., Tillema, J. M., Yang, B., Abdulrahman, Y., Guo, K., Vorasoot, N., Valencia Sanchez, C., Tajfirouz, D. A., …, & Flanagan, E. P. (2024). Diagnostic Utility of MOG Antibody Testing in Cerebrospinal Fluid. Annals of Neurology, 96(1), 34-45. https://doi.org/10.1002/ana.26931
Vancouver
Redenbaugh V, Fryer JP, Cacciaguerra L, Chen JJ, Greenwood TM, Gilligan M, et al. Diagnostic Utility of MOG Antibody Testing in Cerebrospinal Fluid. Annals of Neurology. 2024;96(1):34-45. doi:10.1002/ana.26931
BibTeX
@article{Redenbaugh2024,
author = {Redenbaugh, Vyanka and Fryer, James P and Cacciaguerra, Laura and Chen, John J and Greenwood, Tammy M and Gilligan, Michael and Thakolwiboon, Smathorn and Majed, Masoud and Chia, Nicholas H and McKeon, Andrew and Mills, John R and Lopez Chiriboga, A Sebastian and Tillema, Jan-Mendelt and Yang, Binxia and Abdulrahman, Yahya and Guo, Kai and Vorasoot, Nisa and Valencia Sanchez, Cristina and Tajfirouz, Deena A and Toledano, Michel and Zekeridou, Anastasia and Dubey, Divyanshu and Gombolay, Grace Y and Caparó-Zamalloa, César and Kister, Ilya and Pittock, Sean J and Flanagan, Eoin P},
title = {Diagnostic Utility of MOG Antibody Testing in Cerebrospinal Fluid},
journal = {Annals of Neurology},
year = {2024},
volume = {96},
number = {1},
pages = {34--45},
doi = {10.1002/ana.26931}
}
EUVIMED